Tag Archives: OPK

Top 10 Value Stocks To Own For 2018

We are interrupting our series on the value of your business for this important news regarding another major tax victory for business sellers.

Roughly 200 years ago, in an effort to promote commerce among the states and to stabilize their economies, the federal government established the United States Bank.  One of the states thought to tax it . . . which, today, would seem absurd.  The key legal concept on which the case turned was this: the power to tax is the power to destroy . . . and the power to regulate.  Hold that thought.

For about 20 years, there has been a type of trust that 1) keeps assets in the individuals estate but 2) pays the income tax on its income as a separate taxpayer.  Weve written about this type of trust a few times.  The generic name is the incomplete-gift, non-grantor trust or ING trust.

The incomplete-gift means the trusts assets are still in your estate and, at death, you say who gets the money.  And, because transfers to the trust are incomplete gifts, they are not subject to the gift tax.  The non-grantor is tax-speak for the trust being a stand-alone taxpayer for income tax purposes.  Importantly, the IRS has issued over 80 separate rulings confirming these tax characteristics.  Click here to see one such ruling.

Top 10 Value Stocks To Own For 2018: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

Top 10 Value Stocks To Own For 2018: National Health Investors, Inc.(NHI)

Advisors’ Opinion:

  • [By Monica Gerson]

    National Health Investors Inc (NYSE: NHI) is expected to post its quarterly earnings at $1.17 per share on revenue of $57.82 million.

    Berkshire Hathaway Inc. (NYSE: BRK.B) is projected to post its quarterly earnings at $1.75 per share.

Top 10 Value Stocks To Own For 2018: Navistar International Corporation(NAV)

Advisors’ Opinion:

  • [By Lee Jackson]

    Navistar International Corp. (NYSE: NAV) was started with a Buy rating and a $36 price objective at Aegis Capital. That compares with a consensus target of $24.08. The 52-week range is $5.78 to $32.84. The stock closed yesterday at $30.93.

  • [By Lee Jackson]

    Icahn also was a buyer last week of Navistar International Corp. (NYSE: NAV). He acquireda total of 423.404 shares of the truck and engine maker at prices that ranged from $25.37 to $25.92. The total for the buy was listed at $11 million. The stock closed Friday at $27.49, so it looks like another well-timed buy. The 52-week range for the shares is $10.30 to $33.46, and the consensus price target is $26.79.

Top 10 Value Stocks To Own For 2018: Cotiviti Holdings, Inc. (COTV)

Advisors’ Opinion:

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

Top 10 Value Stocks To Own For 2018: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

Top 10 Value Stocks To Own For 2018: Progressive Corporation (The)(PGR)

Advisors’ Opinion:

  • [By Chris Lange]

    Progressive Corp. (NYSE: PGR) is set to report its third-quarter results Tuesday morning as well. The analysts consensus estimates are $0.36 in EPS on revenue of $6.99 billion. Shares were changing hands at $48.67 on Fridays close. The consensus price target is $49.07, and the 52-week range is $30.99 to $49.75.

Top 10 Value Stocks To Own For 2018: Time Warner Inc.(TWX)

Advisors’ Opinion:

  • [By Lee Jackson]

    Time Warner Inc. (NYSE: TWX) was downgraded to Hold from Buy at Brean Capital. The 52-week range is $55.53 to $96.57. The consensus price target is $102.34. With the shares closing at $96.46, this could also be a valuation call.

  • [By Matthew Briar]

    The phrase “over the top television” or “OTT” for short, aren’t exactly new terms. The phrase/abbreviation was coined shortly after Netflix, Inc. (NASDAQ:NFLX) became a viable alternative to traditional cable television subscriptions a little less than a decade ago. The over-the-top battle didn’t get heated, though, until the past few months. But, now that some more gladiators are in the arena, sparks are starting to fly.

    They’re still flying too, and should do so for a while if a small startup called Viva Entertainment Group Inc (OTCMKTS:OTTV) has anything to do with it it. See, while Netflix, Hulu — jointly owned by Time Warner, Walt Disney Co (NYSE:DIS) and Twenty-First Century Fox Inc (NASDAQ:FOXA) — and a whole slew of other new players in this market may want to take notice of this up-and-comer. At the same time, investors may want to take a step back and look at where the real money in the OTT business is going to be made over the course of the next several years. OTTV plays a prominent role in that picture.

    Contrary to popular belief, Netflix isn’t the dominant name it used to be in the Internet-delivered television industry. Yes, it was the first on the scene as such was was able to carve out the biggest piece of the market. It’s largely become a commoditized business in the meantime though.

    For example, outside of Hulu and Netflix, CBS Corporation (NYSE:CBS) has jumped into the fray with a service called CBS All Access. The product allows subscribers -for a nominal monthly fee – access a variety of CBS programming via the Internet. HBO, from Time Warner Inc (NYSE:TWX), has found some measurable success with its subscription-based Internet television service called HBO Go.

    Sling TV, from DISH Network Corp (NASDAQ:DISH), is another one of the alternatives to the alternative that’s truly made a dent in the over the top market…. by aggregating a variety of television channels into an entire package and then selling that p

  • [By Ashley Moore]

    Here are all three of our top stocks to short…

    Best Stocks to Short No. 3: Time Warner Inc. (NYSE: TWX)

    For the first three quarters of 2016, Time Warner Inc. (NYSE: TWX) adjusted earnings slightly. The changes mostly reflected currency exchange rate fluctuations.

Top 10 Value Stocks To Own For 2018: Wynn Resorts, Limited(WYNN)

Advisors’ Opinion:

  • [By Travis Hoium]

    But Las Vegas Sands Corp. (NYSE:LVS) may not have had as strong a quarter as competitors like Melco Crown Entertainment Ltd (NASDAQ:MPEL) and Wynn Resorts, Limited (NASDAQ:WYNN). We’ll have to wait until the latter two report earnings to see how market share is trending, but Las Vegas Sands left a lot to be desired from a growth perspective.

  • [By Lee Jackson]

    Wynn Resorts Ltd. (NASDAQ: WYNN) hits our insider screens for the second week running. Daniel Wayson, a director at the gaming giant, bought a total of 37,500 shares of the stock at $93.83 per share. The total for the buy was set at $3,518,625. The consensus price target is $98.38. The stock changed handsat $88.34 on Friday’s close.

  • [By Craig Jones]

    Speaking on CNBC's "Fast Money Halftime Report", Pete Najarian said he noticed unusually high options volume in Melco Resorts & Entertainment Ltd(ADR) (NASDAQ: MLCO). He explained that traders were buying the November 24 calls Monday. Over 10,000 contracts were traded in the first half of the session and Najarian followed the trade. He already owns the stock and he believes it has some upside potential, because it's lagging behind Wynn Resorts, Limited (NASDAQ: WYNN).

Top 10 Value Stocks To Own For 2018: Opko Health Inc(OPK)

Advisors’ Opinion:

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 11.7% Wednesday to post a new 52-week low of $6.65 after closing at $7.53 on Tuesday. The stock’s 52-week high is $12.15. Volume of more than 15 million was nearly 4 times the daily average of around 4 million shares traded. On Tuesday the company reported a first-quarter loss.

  • [By Cory Renauer]

    Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Cabela’s (NYSE:CAB) and Opko Health (NASDAQ:OPK) stood out by posting greater price declines than the broader market.

    Opko Health fails a trial

    Opko Health shares slumped 19% after the biotech announced disappointing results for one of its most advanced clinical trials. The human growth hormone injection, coded as hGH-CTP, failed to produce a statistically significant improvement over a placebo pill in its phase 3 study.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 3.6% Monday to post a new 52-week low of $6.37 after closing at $6.61 on Friday. The stock’s 52-week high is $12.15. Volume was about 25% higher than the daily average of around 4.6 million shares. The company had no specific news.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped nearly 15% on Thursday to record a new 52-week low of $7.13 against a high of $12.15. The stock closed at $8.37 on Wednesday. Volume was more than 3 times the daily average of around 4.9 million shares. The company reported a worse-than-expected loss after markets closed last night.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Kohlberg Kravis Roberts (KKR) , Opko Health (OPK) and Allergan (AGN) .

    Cramer was bearish on Kimberly-Clark (KMB) , Novartis AG (NVS) , Chemours (CC) and Gulfport Energy (GPOR) .

Top 10 Value Stocks To Own For 2018: TRC Companies Inc.(TRR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of TRC Companies, Inc. (NYSE: TRR) got a boost, shooting up 16 percent to $7.53. TRC posted Q4 earnings of $0.20 per share on revenue of $132.3 million.

cheap stocks

Source: dilbert.com

Bear with me on a little march through recent technology eras. I have been employed or started up technology companies since the days of the mainframe. One could argue the golden age of mainframe computing was the original cloud, where computational heavy lifting was done at a central data center and served up on a local device.

One of my startups was co founded with my son as a cloud company focused on disaster recovery and business continuity, which we named…bizinuity. We started bizinuity in 2012, but the groundwork before that was laid with many years of building relationships in the tech community.

cheap stocks: P.T. Telekomunikasi Indonesia Tbk.(TLK)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Telekomunikasi Indones (Prsr)Tbk PT-ADR (NYSE: TLK), down 4 percent, and China Telecom Corporation Limited (ADR) (NYSE: CHA) down 2 percent.

cheap stocks: Olympic Steel Inc.(ZEUS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Olympic Steel, Inc. (NASDAQ: ZEUS) got a boost, shooting up 17 percent to $22.55. Olympic Steel reported a Q1 net income of $7.7 million, after posting a loss in the year-ago period.

  • [By Lisa Levin]

    Wednesday afternoon, the basic materials shares climbed by 1.09 percent. Meanwhile, top gainers in the sector included Olympic Steel, Inc. (NASDAQ: ZEUS), up 7 percent, and Aluminum Corp. of China Limited (ADR) (NYSE: ACH), up 7 percent.

  • [By Lisa Levin]

    Basic materials sector was the top gainer in the US market on Monday. Top gainers in the sector included Haynes International, Inc. (NASDAQ: HAYN), Cliffs Natural Resources Inc (NYSE: CLF), and Olympic Steel, Inc. (NASDAQ: ZEUS).

  • [By Lisa Levin]

    Basic materials shares gained around 1.89 percent in trading on Tuesday. Meanwhile, top gainers in the sector included Olympic Steel, Inc. (NASDAQ: ZEUS), and Mechel PAO (ADR) (NYSE: MTL).

cheap stocks: Opko Health Inc(OPK)

Advisors’ Opinion:

  • [By Keith Speights]

    Some biotech stocks have made shareholders a lot of money over the last decade. Few, though, have performed as well as Opko Health (NASDAQ:OPK), Incyte (NASDAQ:INCY), and China Biologic Products (NASDAQ:CBPO). These three biotech stocks turned an initial investment of $10,000 into more than $100,000 in just 10 years. Here’s how they did it.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped nearly 15% on Thursday to record a new 52-week low of $7.13 against a high of $12.15. The stock closed at $8.37 on Wednesday. Volume was more than 3 times the daily average of around 4.9 million shares. The company reported a worse-than-expected loss after markets closed last night.

  • [By Cory Renauer]

    Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.

cheap stocks: BlackBerry Limited(BBRY)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For those remaining QWERTY keyboard aficionados out there, BlackBerry (BBRY)  hardware partner TCL launched the BlackBerry KeyOne, a phone that pairs a 4.5-inch display with a physical keyboard and BlackBerry apps/services. It sells for $549 unsubsidized.

  • [By Abdul Jawula] BlackBerry Ltd (BBRY) tries to revive the brand but is it too little too late for BBRY stock?

    BlackBerry (NSDQ:BBRY) had a smartphones market share of 20% in 2009, which has dropped off a cliff to 0.1% in present day. Blackberry has tried to revive the brand many times. However, they had a similar problem likeMicrosoft (NSDQ:MSFT)hadwith the Windows Phone project. Their refusal to adopt Android resulted in their smartphones becoming less-and-less desirable.

  • [By Chris Lange]

    And BlackBerry Ltd. (NASDAQ: BBRY) will share its latest quarterly earnings on Friday. The forecast is for $264.51 million in revenue. Shares were trading most recently at $10.53, in a 52-week range of $6.23 to $11.74. The consensus price target is $9.02.

  • [By Sreekanth Anasa]

    Canada-based BlackBerry Ltd. (NSDQ:BBRY)announced as part of its latest earnings release, that it would become a pure software solutions company, discontinuing its handset business. This made investors apprehensive about BlackBerrys survival. BBRY stock hasn’t done muchin the last one year either. With BlackBerry focusing all its energy on software, where could the next growth engine come from? Could it even take BlackBerry remotely close to its good old glory days? Well, BlackBerry might just have found the answer.

cheap stocks: McDermott International, Inc.(MDR)

Advisors’ Opinion:

  • [By Monica Gerson]

    McDermott International Inc. (NYSE: MDR) reported stronger-than-expected results for its first quarter and lifted its 2016 earnings outlook. McDermott shares jumped 8.45 percent to $4.43 in the after-hours trading session.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

The Investment Case For Ascendis Pharma

Ascendis Pharma (NASDAQ:ASND) caught my eye earlier this year when I was looking at quarterly ownership changes of biotech-focused hedge funds. Many funds were aggressively buying Ascendis over the last few quarters, and the stock is a high conviction name for at least a few of them. However, the stock was up more than 50% at that point, and I decided to put it aside as there were no material catalysts during most of 2017 and wait for some form of a consolidation or a pullback before doing more research. The stock was in consolidation mode for more than six months and broke out in late September following the failure of one of its main competitors in the growth hormone deficiency market. I was actually expecting to pick up shares cheaper after the success of Versartis phase 3 trial but the opposite happened. However, I think Ascendis is a better buy after a 20%+ rally, then it would be on a 15-20% pullback in the case Versartis somavaratan was successful as I believe the market cap gain does not fully reflect the elimination of a competing product which would have had a one-year head-start over Ascendis TransCon hGH.

Ascendis has only one late-stage asset at this point – TransCon hGH, but I am more interested in owning Ascendis because of its TransCon platform rather than just this late-stage candidate. I think that TransCon hGH can at least justify the current valuation and that it could be worth more than $70 by 2020 (fully de-risked), while the rest of the companys pipeline is equally exciting with potential to add value similar to or greater than TransCon hGH in the following years.

The TransCon technology

Ascendis is developing all product candidates with its TransCon technology. TransCon combines the benefits of a conventional prodrug and sustained release technologies and is broadly applicable to proteins, peptides and small molecules. According to Ascendis, TransCon prodrugs predictably release unmodified active parent drugs and may offer advantages that include superior efficacy, safety, tolerability, and compliance, including less frequent dosing and the ability to switch patients to subcutaneous injections from burdensome continuous infusions and less frequent dosing.

What sets TransCon apart is the ability to design prodrugs that predictably release an unmodified active parent drug, allowing administration frequencies from daily up to half-yearly. The company also claims it can design TransCon prodrugs to act systemically or locally in areas that are difficult to treat with conventional therapies.

The improvement of existing products through the use of TransCon also lowers development risks and increases the chances of success in the clinic since we know that the product works in the targeted patient population. It remains to be seen whether TransCon works in the clinic as intended, but clinical and preclinical results the company reported to date look really encouraging.

Growth hormone deficiency market overview

1 in 4,000 children are born with or acquire growth hormone deficiency or GHD. A child with GHD is expected to reach approximately 70% of his/her expected adult height. Continuous treatment from early childhood can restore height to a childs genetic potential. Delayed therapy jeopardizes attaining full height potential and adherence and persistence are also significant factors. Additional pediatric complications include metabolic abnormalities, cognitive deficiencies and poor quality of life. In adults, GHD is associated with premature mortality, increased fat mass, psychiatric-cognitive, metabolic, cardiovascular, muscular and skeletal abnormalities.

The current standard of care is daily injection of human growth hormone (hGH). The market is fragmented with four major players. Novo Nordisks Norditropin is the market leader with $1.3 billion in worldwide sales in 2016 (up 12% Y/Y). Pfizers Genotropin is second, followed by Eli Lillys Humatrope and Roches Nutropin. The worldwide annual sales have exceeded $3 billion in 2016 and pediatric sales account for roughly 80% of total worldwide sales.

Daily hGH therapy has shown to increase growth and improve metabolic effects and is safe, well-tolerated with an essentially pain-free injection. Compliant children initially achieve catch-up growth, enabling them to achieve normal height. Height velocity following this catch-up growth phase normalizes and allows patients to maintain normal growth throughout the treatment period. Patients that are non-compliant achieve lower catch-up growth and fail to achieve expected treatment outcomes. This is the main problem of daily hGH therapies and has motivated many companies to develop a long-acting hGH. And many have failed to develop a safe, effective and well-tolerated long-acting hGH. Versartis somavaratan is the latest failure the drug was safe and well-tolerated but failed to match daily hGHs height velocity in a phase 3 trial.

Going back to compliance, research has shown that it is a big problem, especially in the pediatric market. Persistence tends to drop below 70% after just 12 months of treatment with daily hGH.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-1507229130795795.png

Source: OPKO Health presentation

By the sixth year of treatment, persistence was shown to drop to 20%.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072293209745572.png

Source: OPKO Health presentation

And as mentioned above, poor compliance leads to lower growth.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072293955803285.png

Source: Ascendis presentation

Once-weekly therapies should significantly improve compliance rates as they would reduce the injection burden from 365 times per year to 52 times per year. The GHD market is growing in the low/mid-single digits and I think the growth should accelerate once safe, effective, well-tolerated, easy-to-use long-acting treatments enter the market. Assuming pricing parity with daily hGH, improved compliance should lead to growth acceleration in the 2020s and I think the GHD market will exceed $4 billion by then and that long-acting hGH products should comprise at least 50% of the market by mid-2020s and dominate the market by late 2020s.

Versartis somavaratan was the only company trying to develop a twice-monthly hGH treatment and its failure leaves three long-acting contenders (all targeting once-weekly administration):

Novo Nordisks somapacitan, which is in a phase 3 trial in adults and in a pediatric phase 2 trial. Somapacitan was successful in a Phase 3a study in adults (page 20 of the 1H 2017 report) it has achieved statistical significance versus placebo on the primary endpoint truncal fat percentage decrease as well as significant increases in lean body mass and muscle mass. The pediatric study is behind and I did not find enough information that shows the potential competitiveness of somapacitan. And given the status of the pediatric trial (phase 2 started in 2016), somapacitan is at least three years behind the other two products. OPKO Healths (NYSEMKT:OPK) hGH-CTP (also called lagova, or mod-4023) failed in a phase 3 study in adults due to significant outliers in the placebo group that deviated from the study protocol. OPKO conducted some post-hoc analyses that showed statistical significance for the primary endpoint when those outliers are excluded and the company plans to meet with the FDA to discuss the path forward in adults, but my base case here is that it will need to conduct another phase 3 trial in adults. The phase 2 pediatric study was a success and I think hGH-CTP is one of the potential market leaders. OPKO partnered hGH-CTP with Pfizer and stands to collect royalties on net sales in the adult indication which should transition to a gross profit split of both hGH-CTP and Genotropin if/when approved for the pediatric indication. Ascendis TransCon hGH a potential best-in-class product.

hGH-CTP and TransCon hGH have shown solid efficacy, safety, and tolerability and I think both have the potential for significant disruption of the GHD market. I would leave room for somapacitan here as well, but its clinical profile and market potential remain to be determined and it will be a late-comer (at least three years behind).

TransCon human Growth Hormone (hGH) a potential best-in-class product for growth hormone deficiency

I believe Ascendis TransCon hGH has the potential to become a best-in-class long-acting hGH product. It is the only product candidate that releases unmodified growth hormone, maintaining the same mode of action as daily hGH therapies. In a phase 2 trial, TransCon hGH has shown comparable efficacy to once-daily Genotropin. The height velocity (HV) TransCon hGH achieved was in the 11.9cm to 13.9cm range compared to 11.6cm for Genotropin. At the same weekly dose as Genotropin, TransCon hGHs HV was 12.9cm compared to 11.6cm.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072294565527806.png

Source: Ascendis presentation

Being within the range of daily hGH is important because it is the right amount of growth. Too little is not good as children wont grow to reach their targeted height, and too much hGH can lead to another condition acromegaly, which leads to tissue overgrowth, diabetes, heart disease, stroke and poor quality of life.

It is also important to monitor IGF-1, or insulin-like growth factor 1. IGF-1 amplifies the anabolic effects of hGH, but has insulin-like effects in fat tissue, thus stimulating fat formation. This is in contrast to hGH which stimulates the breakdown of fat. The normal IGF-1 level varies with age, so IGF-1 levels are expressed as IGF-1 standard deviations scores or IGF-1 SDS. The normal range is defined as IGF-1 between -2 and +2 SDS. In the phase 2 trial, the mean IGF-1 response for all TransCon hGH dose levels was maintained in the normal range. Transient point values of IGF-1 SDS of greater than +2 were observed in a small number of patients and only in the high-dose treatment arm, and there were no reports of safety issues in connection with these transient elevations. The high dose will not be used in the phase 3 trial.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072294849289358.png

Source: Ascendis presentation

Safety is also very important and TransCon hGH was safe and well-tolerated:

Adverse events were consistent with daily hGH therapy observed and not different between cohorts. The immunogenic profile was comparable to daily hGH therapy. Injection site tolerability was also comparable to daily hGH therapy. There were no reports of lipoatrophy or nodule formation.

Ascendis is also developing an auto-injector for the administration of TransCon hGH that will be easy-to-use in the pediatric population. The device has a single low-volume injection for all patients of less than 0.6ml and requires a small 31 gauge needle, four millimeters in length and comparable to needles used to administer daily hGH. The device provides for room temperature storage, includes an empty-all design, is expected to last four years and will be enabled for Bluetooth connectivity. Ascendis expects to use the device in the open-label extension study that follows the phase 3 trial and the company plans to launch TransCon hGH with this device if/when approved. Room temperature storage should provide a slight competitive edge over OPKOs hGH-CTP, which needs to be refrigerated.

The annualized HV TransCon hGH achieved in the phase 2 study compares favorably to HV reported in a large pharmaco-epidemiological survey known as KIGS-Pfizer International Growth Database. KIGS is a registry of real-world outcomes from daily growth hormone therapy which includes the negative effect of non-compliance on treatment outcomes. The reduced burden of daily injections with the use of TransCon hGH should improve treatment outcomes. The potential difference between TransCon hGH and the age-matched KIGS historical controls is shown below, assuming phase 2 efficacy is confirmed in longer-term studies. I doubt that real-world compliance with TransCon hGH will be 100%, but I think it should be much better than daily hGH and that treatment outcomes should be better with TransCon hGH. Better treatment outcomes should provide the incentive for physicians and patients to use long-acting hGH.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072295876590123.png

Source: Ascendis annual report

Does somavaratans failure have a negative read-through for TransCon hGH or OPKOs hGH-CTP?

No, I dont think it does. Somavaratans phase 3 results were consistent with results achieved in the phase 2 trial. The problem with somavaratans phase 2 trial is that it did not have an active comparator and the fact that Versartis was comparing the results to historical Norditropin registry results. Somavaratans height velocity in both phase 2 and phase 3 trials was inferior (below 10cm) to those achieved by TransCon hGH and OPKOs hGH-CTP – both had HV above 11cm and both were non-inferior to the active comparator (Pfizers Genotropin in both cases). I think chances of success of both TransCon hGH and hGH-CTP in their respective phase 3 studies are high.

TransCon PTH potential new standard of care for hypoparathyroidism

Hypoparathyroidism is another rare disease Ascendis is targeting. It affects approximately 75,000 patients in the United States. Shires (SHPG) Natpara was launched in 2015 and represents an important advance but it does not address all aspects of the disease. Natpara improves serum calcium and reduces pill burden (patients take a lot of pills otherwise) but does not improve hypercalciuria which results in renal complications of the disease and/or may contribute to them. Prior to Natpara, the standard of care included oral calcium and vitamin D, and off-label use of Forteo, which, based on Natparas slow uptake, are still being widely used.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072299729912474.png

Source: Ascendis presentation

Ascendis believes it can address the shortcomings of current therapies and that TransCon PTH can be a true enzyme replacement therapy it is designed as a sustained-release prodrug, providing free PTH in the physiological range over 24 hours with once-daily dosing. The development risk for hypoparathyroidism is lower for TransCon PTH than it would be for a new compound since Ascendis is using what we know works. TransCon PTH is based on parent drug teriparatide (Forteo) with clinical proof of principle. Preclinical data have also demonstrated that daily injections of TransCon PTH provide the desired target profile of physiological PTH replacement.

Phase 1 trial was initiated recently and the company expects to skip the phase 2 trial and go directly to the phase 3 trial. The reason for moving directly from phase 1 to phase 3 is the knowledge of the active compound and the fact it demonstrated efficacy in hypoparathyroidism and the company also said that the PK/PD profile is the same in healthy volunteers and in patients (which should be demonstrated in the phase 1 trial). The pivotal trial is expected to start in 2018 and Ascendis expects TransCon PTH to reach the market (assuming it is successful in the clinic) at roughly the same time as TransCon hGH.

As mentioned above, the addressable market in the U.S. is 75,000 patients, and 10% market share translates to roughly $750 million in annual sales. Natparas disappointing uptake is a reason to be cautious about peak sales estimates, but Natpara is not doing that bad it reached a $155 million annualized run rate in Q3 2017 (thats U.S. only for now) after roughly two years on the market despite the above-mentioned shortcomings. If TransCon PTHs clinical profile looks like what Ascendis expects, I believe this could be a $2 billion+ drug in the 2020s (worldwide sales) and that it is potentially more valuable than TransCon hGH as it would be far more differentiated in hypoparathyroidism than TransCon hGH would be in GHD.

Source: Shire earnings reports

TransCon CNP targeting achondroplasia

TransCon CNP represents another lower-risk development opportunity for Ascendis. It is being developed for achondroplasia, the most common form of dwarfism. There are currently no FDA-approved pharmacological treatments and patients often face multiple invasive surgeries to alleviate its many complications. Administration of CNP and its analogs has been demonstrated to stimulate growth in preclinical models. BioMarin (NASDAQ:BMRN) has a clinical candidate vosoritide (daily injections of CNP analog) in development and has presented positive phase 2 data in October 2016 it increased height velocity from baseline by approximately 50% after 12 months of treatment. Vosoritides phase 2 results and Ascendis preclinical results indicate that treatment with systemic CNP could be a promising therapy for achondroplasia.

TransCon CNP is designed as a once-weekly formulation of a CNP peptide and Ascendis believes it could address the fundamental limitations of daily administration of CNP:

CNP released from TransCon CNP maintains small enough size to allow penetration into the growth plates of patients who may use the treatment. TransCon CNP is designed to avoid hypotension, which is a problem with CNP.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072302214648368.png

Source: Ascendis presentation

TransCon CNP has a half-life of approximately 75-hours, a substantial increase to wild-type CNP which has a half-life of 2 minutes and vosoritide, which has a 20-minute half-life. The company believes this substantial half-life extension would enable once-weekly dosing that could achieve higher overall CNP exposure levels in the body with improved tolerability due to low peak serum concentration and that it could improve efficacy and avoid hypotension associated with daily injections of CNP analogs.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072303083393955.png

Source: Ascendis presentation

Achondroplasia affects approximately 250,000 patients worldwide and Ascendis estimates the annual opportunity north of $1 billion. BioMarins vosoritide could come to market sooner and help establish the pricing benchmark and make peak sales estimates more accurate. Vosoritide peak sales estimates are north of $1 billion and up to $2 billion.

Partnerships provide additional technology platform validation

In addition to (soon to be) three clinical-stage drug candidates, Ascendis also has two partnered programs:

TransCon ranibizumab (Lucentis) Roche/Genentech. The goal is to develop a half-year injection of ranibizumab, Genentechs anti-VEGF product, thereby reducing injection frequency and associated patient burden. The worldwide anti-VEGF sales exceeded $7 billion in 2014, with Regenerons Eylea and Lucentis generating the major part of those sales (Lucentis generated approximately $1.4 billion in net sales in 2016). The application of the TransCon technology should allow predictable release of the unmodified drug with up to half-yearly administration. Genentech is currently conducting preclinical studies. Genentech paid $20 million upfront and Ascendis is eligible to receive up to $100 million in milestones for ranibizumab and up to $80 million for each compound not containing ranibizumab (the agreement is not limited to ranibizumab). Ascendis is also eligible to receive tiered royalties on net sales starting in the mid-single digits but not exceeding low-double digits for ranibizumab and in the mid-single digits for compounds not containing ranibizumab. TransCon peptides Sanofi (NYSE:SNY). The two companies are researching and developing prodrugs for the treatment of diabetes. Ascendis received 25 million upfront and is eligible to receive up to an aggregate of 170 million in development and regulatory milestones for the first two products and up to 100 million in sales-based milestones.

Both programs are preclinical and we have yet to see a candidate move into the clinic, but the interest and commitment of two large pharma companies provide additional validation of Ascendis technology platform.

Ascendis is also developing TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a $4 billion-plus worldwide market opportunity. Treprostinil is the active ingredient in Remodulin, developed by United Therapeutics (NASDAQ:UTHR) and Ascendis is developing an inhaled formulation of TransCon Treprostinil for once-daily administration and a formulation designed as a once-daily subcutaneous injection with the goal to offer the same efficacy as infused prostacyclins with a safer and improved tolerability profile. In April 2015, Ascendis announced phase 1 data which showed dose-dependent increases in plasma treprostinil levels, but injection-site tolerability issues did not meet the criteria defined in the target product profile and the company is now working on two new formulations. TransCon Treprostinil is outside of Ascendis area of interest and it plans to partner this candidate.

In addition to the three promising pipeline candidates and the collaborations with Genentech and Sanofi, Ascendis technology platform has the potential for additional applications and the pipeline will likely expand in the following years with in-house and out-licensed products.

Valuation

I believe TransCon hGH alone, in its current state, is worth between $35 and $46 per share. De-risking of TransCon hGH in 2019 (moving the probability of approval to 100% and reducing the time to peak sales by 2 years) results in a valuation range of $76 to $100. The $1-1.2 billion annual sales estimate is based on 25-30% market share of what I believe will be a $4 billion-plus market in the 2020s and TransCon hGH and OPKOs hGH-CTP splitting the market and taking (at least) 50%+ market share from daily hGH therapies if they are proven to be effective, safe and well-tolerated in phase 3 trials and in the real world following their respective approvals. I am leaving some room for Novo Nordisks somapacitan as well, though its clinical profile remains to be determined. Please notice that I am using a 44 million share count and that the current, fully diluted share count is around 40 million. I included a 4 million share buffer to account for additional dilution as the company will likely need more capital for TransCon hGHs commercial launch.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072288183954878.png

Source: authors estimates

There is also a super-bullish scenario here for TransCon hGH – if OPKO’s hGH-CTP fails in the pediatric phase 3 trial or if it shows an unfavorable safety profile. In such a case, TransCon hGH would become the only long-acting player (assuming it is successful in its phase 3 trial, of course) and I think it could fetch 50% market share by mid-2020s, which would translate to roughly $2 billion in annual sales.

I think TransCon PTH could be as valuable as TransCon hGH in 2-3 years, if not more valuable as it would be the unmatched standard of care for hypoparathyroidism and TransCon CNP could also prove to a be a very valuable and differentiated asset. So, I think the upside potential for Ascendis is substantial even if just one of the three products reaches the market. Additional upside could come from Genentech and Sanofi collaborations and from partnering/moving forward the TransCon Treprostinil candidate.

Financial overview

Ascendis is in very good financial shape. The company used the late-September rally to raise $145 million and ended Q3 with 222.5 million (approximately $260 million) in cash and equivalents on a pro-forma basis (the underwriters took advantage of the overallotment option in early Q4). Cash burn in Q3 2017 was roughly $35 million but will probably increase in 2018 since two candidates are advancing into the clinic in the following months/quarters. The company may need to raise additional funds in late 2018 or in 2019, but it also has other options to raise cash it could partner one or more of its three candidates. The company said it intends to keep the U.S. rights and that it might partner outside of the U.S. Given the size of the addressable markets, strong pricing and potential differentiation of these three products, ex-U.S. partnerships could bring solid upfront and future milestone payments and generous royalty rates. But we may have to wait for positive phase 3 results of TransCon hGH to get partners really interested considering the high failure rates of long-acting hGH products.

Significant insider ownership and institutional accumulation

Based on Ascendis 2016 annual report, board members and senior management own approximately 10 million shares (roughly 20% of outstanding shares after the September offering). I havent seen any changes in insider ownership since then and assume their stakes are still substantial. Seeing such strong ownership and no insider sales is always a good sign.

https://static.seekingalpha.com/uploads/2017/10/5/4987661-15072286477385406.png

Source: Ascendis 2016 annual report

And as mentioned in the introduction, strong institutional sponsorship is what attracted my attention in the first place. For a $1.3 billion company, Ascendis has really broad institutional ownership and is a high-conviction name for several biotech-focused funds. The offering in late Q3 has drawn additional interest.

Source: WhaleWisdom

Risks

The risks to the thesis are the usual ones for a development stage biotech company:

One or all candidates may fail in the clinic based on currently available data, this seems unlikely but is nonetheless possible. Even if they reach the market, the products might not live up to their potential due to competition, safety, tolerability or efficacy issues. The company will need to raise additional capital in the following years unless it partners one or more late-stage assets in the next 12-24 months. Raising capital could prove to be difficult if we see one or more setbacks of TransCon hGH and/or the other two candidates. Industry-related headwinds, such as pricing and/or reimbursement in the U.S. and elsewhere could reduce the peak sales potential of all of the companys products. Conclusion

I believe Ascendis TransCon technology platform is underappreciated and that TransCon hGH alone could drive significant upside in the following years. The company should soon have two late-stage assets as TransCon PTH should move from a phase 1 trial straight to a phase 3 trial in 2018 and TransCon CNP should not be far behind these two candidates. The company is in strong financial shape after the September equity raise. Important catalysts over the next two years include:

TransCon hGH enrollment closing by the end of 2017. This is not exactly a strong catalyst but will provide a timeline for the phase 3 readout in late 2018/early 2019. TransCon PTH phase 1 results in healthy volunteers in Q1 2018 (it could be as soon as early January, at the JP Morgan Healthcare conference, according to management comments on the Q3 earnings call) followed by the phase 3 trial initiation in 2018. TransCon CNP moving into the clinic in early 2018 phase 1 trial in healthy volunteers. TransCon hGH phase 3 topline results in late 2018/early 2019. This is by far the most important catalyst for the stock in the next two years. Partnered programs (Genentech, Sanofi) moving into the clinic no timeline here, the company did not provide any guidance. TransCon Treprostinil partnership and/or ex-U.S. partnership for TransCon hGH or other two candidates no timelines here either but possible in 2018 or 2019. Additional products entering the clinic and/or additional partnership announcements.

The stock is near all-time highs as a write this and could be considered as extended in the near-term, but I am not buying it for a short-term bounce or momentum run, this is a long-term investment with significant value creation potential. And what seems like a high price right now often proves to be a bargain in the long run. Of course, I would like to buy it cheaper if possible and will look to continue building my stake in the following weeks. I also think that the market has not fully accounted Versartis failure the stock is up roughly 25% since the failure, adding approximately $300 million to its market cap and a potential competitor with a 1+ year head-start that would have taken solid market share is now out of the picture. Based on my current model for TransCon hGH and the assumed market share split between OPKOs hGH-CTP and TransCon hGH, the elimination of somavaratan is worth at least $11-12 per share (or a third of the low-end of the valuation range) and probably more. I actually like Ascendis more at $35 with somavaratan out of the picture than I would have liked it at $25 for example with somavaratan approved and with a one-year head-start.

Thank you for reading this Seeking Alpha PRO article. PRO members received early access to this article and get exclusive access to Seeking Alpha’s best ideas. Sign up or learn more about PRO here.

Disclosure: I am/we are long ASND, OPK.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article reflects the author’s personal opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

About this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.Tagged: Investing Ideas, Long Ideas, Healthcare, Editors’ Picks, PROWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here

Top 10 High Tech Stocks To Buy Right Now

While US markets continue to head to new highs almost daily at this point, there is one stock that continues to head in the opposite direction. Shipping name DryShips (NASDAQ:DRYS) continues to fall after its latest $200 million share sale agreement with Kalani Investments. As more and more dilution adds up, shares continue to plummet, as seen below:

(Source: Yahoo! Finance)

At this point, DryShips basically is selling a large block of stock to Kalani every week. Before this second Kalani deal started, a little more than 36 million shares were outstanding. After last week’s sale, that number had soared to more than 58 million, and much of the Kalani deal was still pending. Well, after the bell on Friday, DryShips filed another 6-K detailing the latest round of this deal.

Top 10 High Tech Stocks To Buy Right Now: Sohu.com Inc.(SOHU)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Sohu.com (SOHU) is a Chinese online media, search, gaming, community and mobile service group. This stock closed up 7.5% to $69.61 in Monday’s trading session.

    Monday’s Volume: 4.90 million

    Three-Month Average Volume: 1.01 million

    Volume % Change: 351%

    From a technical perspective, SOHU ripped sharply higher here with heavy upside volume. This move pushed shares of SOHU into breakout territory, since the stock took out some near-term overhead resistance at $67.80. Shares of SOHU are now quickly moving within range of triggering another breakout trade. That trade will hit if SOHU manages to take out Monday’s high of $69.71 to its 52-week high at $70.63 with high volume.

    Traders should now look for long-biased trades in SOHU as long as it’s trending above Monday’s low of $66.95 or above that first breakout level of $67.80 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.01 million shares. If that breakout hits soon, then SOHU will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $75 to $80.

  • [By Belinda Cao]

    Sohu.com Inc. (SOHU), which sold a stake in its search unit to Tencent Holdings Ltd. (700), advanced 11 percent for the week to $72.06. It retreated 5.9 percent Sept. 20. Tencent, Chinas biggest Internet company by market value, paid $448 million for a 36.5 percent stake in Sohus Sogou unit last week and merge its own search service with Sogou.

  • [By Monica Gerson]

    Sohu.com Inc (NASDAQ: SOHU) is projected to report a quarterly loss at $0.57 per share on revenue of $406.50 million.

    Bank of Hawaii Corporation (NYSE: BOH) is expected to report its quarterly earnings at $0.99 per share on revenue of $149.88 million.

Top 10 High Tech Stocks To Buy Right Now: Cellcom Israel Ltd.(CEL)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

Top 10 High Tech Stocks To Buy Right Now: Opko Health Inc(OPK)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Cabela’s (NYSE:CAB) and Opko Health (NASDAQ:OPK) stood out by posting greater price declines than the broader market.

    Opko Health fails a trial

    Opko Health shares slumped 19% after the biotech announced disappointing results for one of its most advanced clinical trials. The human growth hormone injection, coded as hGH-CTP, failed to produce a statistically significant improvement over a placebo pill in its phase 3 study.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped nearly 15% on Thursday to record a new 52-week low of $7.13 against a high of $12.15. The stock closed at $8.37 on Wednesday. Volume was more than 3 times the daily average of around 4.9 million shares. The company reported a worse-than-expected loss after markets closed last night.

  • [By Cory Renauer]

    Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 3.6% Monday to post a new 52-week low of $6.37 after closing at $6.61 on Friday. The stock’s 52-week high is $12.15. Volume was about 25% higher than the daily average of around 4.6 million shares. The company had no specific news.

  • [By Keith Speights]

    Some biotech stocks have made shareholders a lot of money over the last decade. Few, though, have performed as well as Opko Health (NASDAQ:OPK), Incyte (NASDAQ:INCY), and China Biologic Products (NASDAQ:CBPO). These three biotech stocks turned an initial investment of $10,000 into more than $100,000 in just 10 years. Here’s how they did it.

Top 10 High Tech Stocks To Buy Right Now: Advanced Semiconductor Engineering, Inc.(ASX)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, technology shares rose by just 0.2 percent. Meanwhile, top losers in the sector included Advanced Semiconductor Engnrng Inc (ADR) (NYSE: ASX), down 6 percent, and Bitauto Hldg Ltd (ADR) (NYSE: BITA) down 6 percent.

  • [By Peter Graham]

    A look at the long term performance of small cap Amkor Technology along with Taiwan based peers like large cap mid cap Siliconware Precision Industries (NASDAQ: SPIL) and Advanced Semiconductor Engineering (NYSE: ASX) show considerable volatility:

  • [By Lisa Levin]

    In trading on Tuesday, technology shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Advanced Semiconductor Engnrng Inc (ADR) (NYSE: ASX), down 6 percent, and QAD Inc. (NASDAQ: QADB) down 5 percent.

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

    Read more of Cramer’s comments about the stocks in the Lightning Round.

Top 10 High Tech Stocks To Buy Right Now: Telecom Italia S.P.A.(TI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, telecommunications services shares fell by 0.29 percent. Meanwhile, top losers in the sector included Telecom Italia SpA (ADR) (NYSE: TI), down 4 percent, and Internet Initiative Japan Inc. (ADR) (NASDAQ: IIJI), down 3 percent.

Top 10 High Tech Stocks To Buy Right Now: Prudential Financial Inc.(PRU)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

    Read more of Cramer’s comments about the stocks in the Lightning Round.

  • [By WWW.MONEYSHOW.COM]

    Prudential Financial (PRU) is also a major provider of asset management and retirement services. It focuses is on fixed income, a major liability during the past eight years of ultra-low interest rates.

  • [By Chuck Saletta]

    Prudential Financial (NYSE:PRU) has long had the Rock of Gibraltar as its corporate symbol, representing its solid financial position. With more cash and equivalents than debt on its balance sheet, and a total cash hoard of over $49 billion, Prudential still looks set up to handle some downright awful insurable losses. That’s its “Rock of Gibraltar” strength showing through.

Top 10 High Tech Stocks To Buy Right Now: Polycom Inc.(PLCM)

Advisors’ Opinion:

  • [By Emily Stewart]

     Polycom (PLCM) is Soros’ top tech holding. As of the end of the second quarter, he owns 7.9 million shares valued at $89.2 million.

    Polycom provides collaboration solutions for voice, video, and content sharing. It has a $1.7 billion market cap and trades at a P/E of 73.24.

Top 10 High Tech Stocks To Buy Right Now: Profire Energy, Inc.(PFIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Profire Energy, Inc. (NASDAQ: PFIE) is estimated to post its quarterly earnings at $0.00 per share on revenue of $6.74 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 High Tech Stocks To Buy Right Now: Karyopharm Therapeutics Inc.(KPTI)

Advisors’ Opinion:

  • [By Chris Lange]

    Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was raised to a Buy rating from Hold, and the price target was increased to $12 from $9, at Jefferies. The firm said its call is based on its future revenue opportunity in multiple myeloma. Itsshares most recently closed at $10.62, with a consensus price target of $16.30 and a 52-week range of $4.83 to $19.41.

Top 10 High Tech Stocks To Buy Right Now: Snyder's-Lance, Inc.(LNCE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Snyder’s-Lance Inc (NASDAQ: LNCE) is estimated to report its quarterly earnings at $0.23 per share on revenue of $470.33 million.

    Examworks Group, Inc. (NYSE: EXAM) is projected to post its quarterly earnings at $0.08 per share on revenue of $217.47 million.

what is share market

11 Sales Pitches That Kill Sales

5 Reasons Genworth’s Would-Be Buyer Could Still Close the Deal

ACA Healthy Enrollee Bills Pound Aetna and Kaiser: Mark Farrah

The Treasury bill yield curve says the probability that the U.S. government won’t raise the debt ceiling in time to avert a technical default — a failure to make an interest payment on time — is about 15%.

That’s based on a simple formula that looks at the elevated yields on bills that mature around the time the government is expected to exhaust its borrowing authority in mid-October, compared with the yields on bills due before and after.

Copyright 2017 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. padding: 0px 81px;width: inherit; Retirement Wire

Your resource for news, research and analysis to help you deliver more effective outcomes to your clients. Resources Guide: How One Advisor Turned $3k into $15M in 9 Months

Kick-start your practice with one advisor’s winning formula.

what is share market: Kona Grill Inc.(KONA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Kona Grill Inc (NASDAQ: KONA) was down, falling around 25 percent to $2.00 after the company reported downbeat quarterly results.

    Commodities

what is share market: Cytokinetics, Incorporated(CYTK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cytokinetics, Inc. (NASDAQ: CYTK) shares dropped 27 percent to $8.12 on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv in a late-stage study. The results of the international Phase 3 study showed tiraemtive did not meet the primary endpoint of change from baseline in slow vital capacity, or SVS, evaluated at 24 weeks, as well the secondary endpoints evaluated at 48 weeks.

  • [By Paul Ausick]

    Cytokinetics Inc. (NASDAQ: CYTK) dropped about 37% Tuesday to post a new 52-week low of $7.00 after closing at $11.10 on Monday. The 52-week high is $17.20. Volume was around 7 million, about 14 times the daily average of less than 500,000. The company’s ALS drug failed ti meet its endpoint in a phase 3 study.

  • [By Chris Lange]

    Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesdays session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, the firms Phase 3 clinical trial of tirasemtiv did not meet the primary endpoint or any of the secondary endpoints.

what is share market: Bridgford Foods Corporation(BRID)

Advisors’ Opinion:

  • [By Lisa Levin]

    Non-cyclical consumer goods & services sector was the top gainer in the US market on Tuesday. Top gainers in the sector included Nature's Sunshine Prod. (NASDAQ: NATR), Bridgford Foods Corporation (NASDAQ: BRID), and SunOpta, Inc. (USA) (NASDAQ: STKL).

  • [By Lisa Levin]

    In trading on Friday, non-cyclical consumer goods & services shares rose by just 0.3 percent. Meanwhile, top losers in the sector included Medifast Inc (NYSE: MED), down 5 percent, and Bridgford Foods Corporation (NASDAQ: BRID), down 6 percent.

what is share market: Opko Health Inc(OPK)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Cabela’s (NYSE:CAB) and Opko Health (NASDAQ:OPK) stood out by posting greater price declines than the broader market.

    Opko Health fails a trial

    Opko Health shares slumped 19% after the biotech announced disappointing results for one of its most advanced clinical trials. The human growth hormone injection, coded as hGH-CTP, failed to produce a statistically significant improvement over a placebo pill in its phase 3 study.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Kohlberg Kravis Roberts (KKR) , Opko Health (OPK) and Allergan (AGN) .

    Cramer was bearish on Kimberly-Clark (KMB) , Novartis AG (NVS) , Chemours (CC) and Gulfport Energy (GPOR) .

  • [By Cory Renauer]

    Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 11.7% Wednesday to post a new 52-week low of $6.65 after closing at $7.53 on Tuesday. The stock’s 52-week high is $12.15. Volume of more than 15 million was nearly 4 times the daily average of around 4 million shares traded. On Tuesday the company reported a first-quarter loss.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 3.6% Monday to post a new 52-week low of $6.37 after closing at $6.61 on Friday. The stock’s 52-week high is $12.15. Volume was about 25% higher than the daily average of around 4.6 million shares. The company had no specific news.

what is share market: Sunoco LP(SUN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on August 3, 2016.

    J B Hunt Transport Services Inc (NASDAQ: JBHT) – $0.2200 dividend, 1.0791 percent yield
    Johnson Controls Inc (NYSE: JCI) – $0.2900 dividend, 2.6250 percent yield
    FirstEnergy Corp. (NYSE: FE) – $0.3600 dividend, 3.9680 percent yield
    Sunoco LP (NYSE: SUN) – $0.8255 dividend, 10.7347 percent yield
    Wells Fargo & Co (NYSE: WFC) – $0.3800 dividend, 3.1588 percent yield
    BP plc (ADR) (NYSE: BP) – $0.6000 dividend, 6.8768 percent yield
    American Airlines Group Inc (NASDAQ: AAL) – $0.1000 dividend, 1.1442 percent yield
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) – $0.1300 dividend, 2.9834 percent yield
    Alcoa Inc (NYSE: AA) – $0.0300 dividend, 1.1321 percent yield
    Sensient Technologies Corporation (NYSE: SXT) – $0.2700 dividend, 1.5341 percent yield

    Posted-In: Ex-DividendNews Dividends Markets Trading Ideas

  • [By Douglas A. McIntyre]

    Exxon Mobil Corp. (NYSE: XOM) is the second largest company in America and the world’s largest oil company. Chevron Corp. (NYSE: CVX) is the third largest company in the United States. Valero Corp. (NYSE: VLO) is among the world’s largest refiners. Sunoco L.P. (NYSE: SUN) is one of North America’s largest owners of stations and convenience stores. BP PLC (NYSE: BP) is among the world’s oil behemoths. Shell is the U.S. branch of oil giant Royal Dutch Shell PLC (NYSE: RDS-A).

what is share market: Evoke Pharma, Inc.(EVOK)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Evoke (Nasdaq: EVOK) is a pharmaceutical company that develops drug candidates intended to treat gastrointestinal diseases. EVOK rose 73% last month after it announced positive guidance from the FDA for Gimoti, a patented nasal delivery drug that is intended to treat gastroparesis in adult women. The positive results were from a second pre-NDA (New Drug Application) meeting Evoke had with the FDA. EVOK is currently trading at $2.67 per share and is down 9.83% as of Jan. 9 YOY.

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

Top 10 Undervalued Stocks To Invest In Right Now

Talk about a Barron’s bounce!Range Resources (RRC) has soared to the top of the S&P 500 today after Barron’s touted it in the pages of the magazine this weekend.

Agence France-Presse/Getty Images

Range Resources gained 4.1% to $28.47, while the S&P 500 slipped 0.3% to2,375.31.

Barron’s Andrew Bary called Range Resources “an unappreciated energy play.” He explains why:

With major market indexes at record highs, natural-gas stocks are among the few depressed industry groups. Blame a warm winter and weakening gas prices.

Range Resources (ticker: RRC), a leading U.S. gas producer, looks undervalued. Its shares, at $27, are down 20% this year and are much below their 52-week high of $47, set last June. Range drilled the first well in the now-prolific Marcellus region of Pennsylvania more than a decade ago and amassed one of its largest land positions there610,000 acres. Its $4.2 billion purchase of Memorial Resource Development last September gave it access to what the company views as a prolific and underappreciated gas region: northern Louisiana

Top 10 Undervalued Stocks To Invest In Right Now: Hatteras Financial Corp(HTS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hatteras Financial (HTS) has jumped 9.4% to $15.60 after agreeing to be purchased byAnnaly Capital Management (NLY) for $1.5 billion.Annaly Capital Management has dropped 1.1% to $$10.30.

Top 10 Undervalued Stocks To Invest In Right Now: Haier Electronics Group Co., Ltd. (HRELF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    2. Appliance Sale – This is another operating segment that the company did not consider core to its business, so management sold the segment to Haier (OTCPK:HRELF) for over $5b. The benefit: Additional capital can be allocated to the core operational areas.

  • [By SEEKINGALPHA.COM]

    The main business units of the Hong Leong Asia are the Diesel Engines Unit – China Yuchai , the Consumer Products Unit – Henan Xinfei (now marketed as “Frestec”), and the Building Materials Unit – BMU. The other business units in the company are the Industrial Packaging Unit – Rex and the Air-conditioning Systems Unit – Airwell. As the majority of the business units namely Yuchai, Xinfei and Airwell, operate in China (more than 80% of total revenue), the continual slowdown of the economic growth in China coupled with increasing competition has adversely affected both the revenue and the profitability. Particularly for the consumer products unit, its small scale has severely impacted its competitiveness given aggressive larger players like Haier (OTCPK:HRELF), Midea, Feilong Electric, and Hefei Meiling.

Top 10 Undervalued Stocks To Invest In Right Now: National Oilwell Varco, Inc.(NOV)

Advisors’ Opinion:

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Applied Materials Inc.(AMAT), Red Hat Inc.(RHT) and National Oilwell Varco Inc.(NOV)

  • [By Shauna O’Brien]

    Jefferies reported on Monday that it has lifted its price target on National-Oilwell Varco, Inc. (NOV).

    The firm has reaffirmed a “Buy” rating on NOV, and has raised the company’s price target from $84 to $91. This price target suggests a 14% increase from the stock’s current price of $78.24.

    Analyst Brad Handler noted that NOV’s weak margin will likely rebound in 2014 and the chances of a dividend increase are high.

    Looking forward, the firm has lifted its order estimates for FY2013 from $10.8 billion to $11.3 billion. FY2014 earnings estimates have been raised from $6.40 to $6.50 per share and FY2015 estimates have been increased from $7.65 to $7.95 per share.

    National-Oilwell Varco shares were up 76 cents, or 0.97% during pre-market trading Monday. The stock is up 14% YTD.

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggestedgoing long on large cap oilfield equipment manufacturer and technology stock National-Oilwell Varco, Inc (NYSE: NOV):

  • [By Tony Daltorio]

    But the best investment in this sector, according to Moors, is National Oilwell Varco Inc. (NYSE: NOV).

    He calls it the “one company that stands to benefit most directly from what is happening in the equipment sector.”

Top 10 Undervalued Stocks To Invest In Right Now: Aerojet Rocketdyne Holdings, Inc. (AJRD)

Advisors’ Opinion:

  • [By William Patalon III]

    So is Aerojet Rocketdyne Holdings Inc. (NYSE: AJRD), the rocket-engine specialist Lockheed has tapped to help develop the “scramjet” engines that will push the Son of Blackbird to six times the speed of sound.

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Jim Robertson]

    Small cap rocket stockAerojet Rocketdyne Holdings (NYSE: AJRD) had ended last week almost 20% higher albeit shares are slipping in early trading this morning. Small cap Aerojet Rocketdyne Holdings, formerly GenCorp, Inc,is a world-recognized aerospace and defense leader that provides propulsion and energetics to the space, missile defense and strategic systems, tactical systems and armaments areas, in support of domestic and international markets. Starting out in 1915 as General Tire & Rubber Company in Akron, Ohio, todayAR Holdings’ is headquartered in California with businesses that include Aerojet Rocketdyne and Easton Real Estate at facilities across the United States and in Europe.

  • [By Rich Smith]

    While Trump’s nuclear tweet appears to have taken some folks off guard, the fact is that the U.S. has been planning a major upgrade and refurbishmentof its nuclear arsenal for quite some time — since at least the early years of the second Obama administration, in fact. As far back as three years ago, we were writing about a U.S. Air Force effort to begin upgrading the nation’s aging fleet of Minuteman III intercontinental ballistic missiles — a contract that Aerojet Rocketdyne (NYSE:AJRD), among others, is counting on to juice its rocket revenues. Rival rocket scientist Orbital ATK (NYSE:OA) is bidding on the same contract, and whether it’s Aerojet or Orbital that eventually ends up winning this piece of the nuclear rearmament project, there should be money aplenty to go around.

Top 10 Undervalued Stocks To Invest In Right Now: Opko Health Inc(OPK)

Advisors’ Opinion:

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 3.6% Monday to post a new 52-week low of $6.37 after closing at $6.61 on Friday. The stock’s 52-week high is $12.15. Volume was about 25% higher than the daily average of around 4.6 million shares. The company had no specific news.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped nearly 15% on Thursday to record a new 52-week low of $7.13 against a high of $12.15. The stock closed at $8.37 on Wednesday. Volume was more than 3 times the daily average of around 4.9 million shares. The company reported a worse-than-expected loss after markets closed last night.

  • [By Paul Ausick]

    Opko Health Inc. (NASDAQ: OPK) dropped about 11.7% Wednesday to post a new 52-week low of $6.65 after closing at $7.53 on Tuesday. The stock’s 52-week high is $12.15. Volume of more than 15 million was nearly 4 times the daily average of around 4 million shares traded. On Tuesday the company reported a first-quarter loss.

  • [By Cory Renauer]

    Shares of multinational pharmaceutical and diagnostics companyOpko Health, Inc. (NASDAQ:OPK)are feeling the heat after reporting fourth-quarter and full-year 2016 earnings. Despite a major thumping late last year, the stock gave up another 10.5% as of 3:31 p.m. on Thursday.

Top 10 Undervalued Stocks To Invest In Right Now: The Rubicon Project, Inc.(RUBI)

Advisors’ Opinion:

  • [By Lisa Levin]

    The Rubicon Project Inc (NYSE: RUBI) shares dropped 28 percent to $6.08. Rubicon Project reported upbeat results for its fourth quarter and named Michael Barrett as CEO.

  • [By Paul Ausick]

    Rubicon Project Inc. (NYSE: RUBI) dropped about 29% Wednesday to post a new 52-week low of $5.96 after closing Tuesday at $8.39. Volume of more than 6.1 million shares was more than 10 times the daily average of less than 600,000. The company named a new CEO and reported weak results after markets closed Tuesday.

  • [By Paul Ausick]

    Rubicon Project Inc. (NYSE: RUBI) dropped about 1.9% Friday, to post a new 52-week low of $5.65 after closing at $5.76 on Thursday. The stock’s 52-week high is $20.37. Volume was nearly 4 times the daily average of around 740,000 shares. The company had no specific news.

  • [By Paul Ausick]

    The Rubicon Project Inc. (NYSE: RUBI) dropped about 2.4% on Tuesday to post a new 52-week low of $8.64 against a 52-week high of $20.37. Volume of around 680,000 million was about 15% below the daily average of around 780,000. The stock closed at $8.85 on Monday night. The ad marketplace has formed a strategic alliance with Flipboard that will allow advertisers to buy ad space on Flipboard.

Top 10 Undervalued Stocks To Invest In Right Now: MEDIFAST INC(MED)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, non-cyclical consumer goods & services shares rose by just 0.3 percent. Meanwhile, top losers in the sector included Medifast Inc (NYSE: MED), down 5 percent, and Bridgford Foods Corporation (NASDAQ: BRID), down 6 percent.

  • [By Lee Jackson]

    These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).

  • [By Peter Graham]

    Although obesity is widespread, small cap dieting stocks havetended to causeinvestor portfolios to loose weight. A long term performance chart shows small cap weight loss or dieting stocks Weight Watchers International and Reliv International, Inc (NASDAQ: RELV) stillbelow or at breakeven for longer term investors whileMedifast Inc (NYSE: MED)has performed better and NutriSystem Inc (NASDAQ: NTRI) hasfinally begun to take offearly last year:

  • [By Peter Graham]

    A long term performance chart shows small cap weight loss or dieting stocks Weight Watchers International and Reliv International, Inc (NASDAQ: RELV) still underperforming whileNutriSystem Inc (NASDAQ: NTRI) and Medifast Inc (NYSE: MED) began taking off early last year:

Top 10 Undervalued Stocks To Invest In Right Now: Edwards Lifesciences Corporation(EW)

Advisors’ Opinion:

  • [By Lisa Levin]

    Breaking news

    Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
    Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
    Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
    Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.

  • [By Ben Levisohn]

    Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.

    Getty Images

    Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.

    Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

    Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.

  • [By Ben Levisohn]

    Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

    Getty Images

    Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

    Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

    Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

    For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…

    As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.

    No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.

Top 10 Undervalued Stocks To Invest In Right Now: Liquidity Services Inc.(LQDT)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Liquidity Service (LQDT) is an online auction marketplace for surplus and salvage assets. This stock closed up 14.9% at $34.44 in Monday’s trading session.

    Monday’s Volume: 1.60 million

    Three-Month Average Volume: 402,622

    Volume % Change: 336%

    From a technical perspective, LQDT skyrocketed higher here right off its 50-day moving average of $30.94 with strong upside volume. This move briefly saw shares of LQDT trend back above its 200-day moving average at $34.60, before it closed just below that level at $34.44. Shares of LQDT are now quickly moving within range of triggering a big breakout trade. That trade will hit if LQDT manages to take out Monday’s intraday high of $35.21 and then once it clears some more near-term overhead resistance at $35.71 with high volume.

    Traders should now look for long-biased trades in LQDT as long as it’s trending above $32.67 or above $31.60 and then once it sustains a move or close above those breakout levels with volume that hits near or above 402,622 shares. If we get that breakout soon, then LQDT will set up to re-test or possibly take out its next major overhead resistance levels at $38 to $40.90.

  • [By Jon C. Ogg]

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

Top 10 Undervalued Stocks To Invest In Right Now: Roche Holding AG (RHHBY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Current biologic top sellers in RA include AbbVie (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Roche (OTCQX:RHHBY), and UCB (OTCPK:UCBJF). The table below shows the drugs marketed by these pharmaceutical giants and relevant details:

  • [By SEEKINGALPHA.COM]

    AbbVie (ABBV) reported positive trial data from its phase 3 study of venetoclax in combination with Roches (OTCQX:RHHBY) Rituxan in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and showed the venetoclax combo extended progression-free survival compared to bendamustine + Rituxan. I recently covered AbbVie and its pipeline and argued that AbbVie has little to replace Humira with in that pipeline.

  • [By SEEKINGALPHA.COM]

    As the graphic below shows, ImmunoGen’s product pipeline is potentially significant. Furthermore, it is impressive to see the involvement and partnerships in these early stage compounds by some of the world’s leading pharmaceutical and biotech companies. This includes firms like Amgen (NASDAQ:AMGN), Roche (OTCQX:RHHBY), Bayer (OTCPK:BAYRY), Sanofi (NYSE:SNY), Eli Lilly (NYSE:LLY), and Novartis (NYSE:NVS).

  • [By SEEKINGALPHA.COM]

    Keytruda is also picking up indications, trading up Thursday on news of a new FDA approval in front line lung cancer treatment (not a big surprise, but there was some doubt). Some adverse news on Roche’s (OTCQX:RHHBY) I-O competitor Tecentriq in bladder cancer led IBD to publish this:

  • [By Keith Speights]

    However, Roche (NASDAQOTH:RHHBY) could beat Corbus to market with Actemra. The drug is already approved for treating rheumatoid arthritis and juvenile idiopathic arthritis. Roche expects to file for approval of Actemra in treating system sclerosis in 2018.

  • [By SEEKINGALPHA.COM]

    There’s still a lot to love about BMY and Opdivo, as they have the potential to be much larger. Now, notable BMY buyers could be the likes of Novartis (NYSE:NVS), Roche (OTCQX:RHHBY) or Pfizer (NYSE:PFE) – PFE has been looking to up its presence in the oncology market, and is also looking for a major purchase. BMY has a strong oncology pipeline that could work well with PFE or even Gilead (NASDAQ:GILD). GILD has an interest in oncology, and has plenty of cash for a buyout.